Skip to main content
TipRanks
Go Ultimate75% OFF

SMS Lifesciences India Ltd. (HALEOSLABS) AI Stock Analysis

1 Followers
IN:HALEOSLABS

SMS Lifesciences India Ltd.

(NSE:HALEOSLABS)

Select Model
Rating:58Neutral
Price Target:INR 1,650.00â–²(3.77% Upside)
Action:reiterated
Date:11/13/26

The score is held back primarily by weakened profitability and deteriorating cash generation (negative FY2026 free cash flow and low cash conversion) despite strong revenue growth and a reasonable balance sheet. Technicals are moderately supportive with the price above major moving averages, but negative MACD signals softer momentum. Valuation is mixed: a high P/E is a headwind, while the unusually high dividend yield provides support.

Positive Factors
Revenue ReboundThe strong FY2026 revenue rebound indicates improving demand for the company’s APIs and intermediates. Sustained top-line recovery would broaden operating scale, strengthen customer relationships across the generic drug value chain, and provide a foundation for future earnings improvement.
Negative Factors
Gross Margin CompressionThe sharp gross-margin contraction indicates materially weaker economics per unit of revenue, whether from pricing, product mix, or input costs described in the results. If persistent, it would limit reinvestment capacity and make revenue growth less valuable to shareholders.

SMS Lifesciences India Ltd. (HALEOSLABS) vs. iShares MSCI India ETF (INDA)

-20%-10%0%10%20%30%IN:HALEOSLABS+19.74%INDA-5.86%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 4.81B
Dividend Yield
0.09%
Average Volume (3M)
90
Price to Earnings (P/E)
37.1
Beta (1Y)
0.99
Revenue Growth
-0.99%
EPS Growth
-30.72%
Country
India
Employees
611
Sector
General
Sector Strength
55
Industry
Biotechnology

SMS Lifesciences India Ltd. Business Overview & Revenue Model

Company Description

Haleos Labs Limited, an Indian-based pharmaceutical enterprise, specializes in the production of crucial active pharmaceutical ingredients (APIs) and intermediate compounds. Their extensive portfolio encompasses a wide array of therapeutic applicatio...

SMS Lifesciences India Ltd. Financial Statement Overview

Summary

Topline momentum improved (FY2026 revenue up ~35% YoY) and leverage appears manageable (debt-to-equity ~0.52), but profitability weakened (gross margin fell sharply to ~14% from ~35%; EBIT margin down) and cash flow is a major concern with low cash conversion and free cash flow turning meaningfully negative in FY2026.

Income Statement

62Positive

Balance Sheet

66Positive

Cash Flow

38Negative
Financial statement breakdown
BreakdownTTMMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue2.47B3.34B3.37B3.00B3.13B2.65B
Gross Profit893.12M480.08M1.17B907.68M845.45M408.72M
EBITDA363.12M446.77M496.44M347.37M338.06M319.58M
Net Income145.41M173.12M201.09M90.93M114.63M135.57M
Balance Sheet
Total Assets04.54B3.90B3.91B3.95B3.05B
Cash, Cash Equivalents and Short-Term Investments11.92M23.69M15.08M14.93M36.10M110.64M
Total Debt01.11B864.09M1.01B1.00B651.63M
Total Liabilities-2.03B2.25B1.78B1.98B2.07B1.76B
Stockholders Equity2.03B2.14B1.97B1.77B1.69B1.29B
Cash Flow
Free Cash Flow262.34M-228.98M187.06M34.38M-338.56M-25.15M
Operating Cash Flow457.63M349.64M340.55M243.06M146.95M330.42M
Investing Cash Flow-192.05M-579.69M-149.98M-184.50M-312.92M-266.22M
Financing Cash Flow-262.87M237.10M-191.24M-65.64M168.88M-310.00K

SMS Lifesciences India Ltd. Technical Analysis

Technical Analysis SentimentPositive
Last Price1590.00

Price Trends

50DMA1502.27Positive
100DMA1513.00Positive
200DMA1443.56Positive

Market Momentum

MACD-6.52Negative
RSI58.93Neutral
STOCH54.88Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:HALEOSLABS, the sentiment is Positive. The current price of 1590.00 is above the 20-day moving average (MA) of 1491.24, above the 50-day MA of 1502.27, and above the 200-day MA of 1443.56, indicating a bullish trend. The MACD of -6.52 indicates Negative momentum. The RSI at 58.93 is Neutral, neither overbought nor oversold. The STOCH value of 54.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:HALEOSLABS.

SMS Lifesciences India Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:HALEOSLABS against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:SUPRIYAIN:SUPRIYA62NeutralINR 50.90B28.72―0.16%23.00%-2.84%
IN:CONCORDBIOIN:CONCORDBIO61NeutralINR 124.39B44.05―1.27%4.02%-12.81%
IN:SYNGENEIN:SYNGENE59NeutralINR 179.51B95.96―0.28%-5.99%-60.30%
IN:HALEOSLABSIN:HALEOSLABS58NeutralINR 4.81B37.12―0.09%-0.99%-30.72%
IN:DCALIN:DCAL57NeutralINR 27.26B39.75――-20.86%-34.51%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IN:BIOCONIN:BIOCON47NeutralINR 597.19B121.75―0.14%5.70%-24.72%

* General Sector Average

Performance Comparison

-40%-20%0%20%IN:HALEOSLABSIN:BIOCONIN:CONCORDBIOIN:DCALIN:SUPRIYAIN:SYNGENEDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:HALEOSLABS and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:HALEOSLABSSMS Lifesciences India Ltd.1590.00297.2723.00%
IN:BIOCONBiocon Limited366.80-54.00-12.83%
IN:CONCORDBIOConcord Biotech Ltd.594.50-151.73-20.33%
IN:DCALDishman Carbogen Amcis Ltd.173.90-77.55-30.84%
IN:SUPRIYASupriya Lifescience Limited632.40-152.82-19.46%
IN:SYNGENESyngene International Ltd.444.70-205.06-31.56%

SMS Lifesciences India Ltd. Corporate Events

Haleos Labs Confirms All Resolutions Passed at 20th AGM Held Online

Oct 1, 2026

Haleos Labs Limited has reported the voting results of its 20th Annual General Meeting held on September 30, 2026, which was conducted via video conferencing. A total of 58 shareholders, including members of the promoter group and public shareholders...

Haleos Labs’ Mahi Drugs Unit Clears USFDA Inspection with No Observations

Sep 18, 2026

Haleos Labs Limited announced that the United States Food and Drug Administration has successfully completed an inspection of its material subsidiary Mahi Drugs Private Limited’s API manufacturing facility at Jawaharlal Nehru Pharma City in Andhra Pr...

Haleos Labs Sets 20th AGM to Approve FY26 Results, Dividend and New Auditor

Sep 8, 2026

Haleos Labs Limited has convened its 20th Annual General Meeting for September 30, 2026, to be conducted via video conferencing and other audio-visual means, reflecting ongoing use of digital platforms for shareholder engagement. Shareholders will re...

Haleos Labs Publishes Notices for 20th AGM in Line with SEBI Norms

Sep 8, 2026

Haleos Labs Limited, formerly SMS Lifesciences India Ltd., is a Hyderabad-based pharmaceutical and life sciences company listed on BSE and NSE under the symbol HALEOSLABS. It uses regional and national business newspapers to disseminate investor info...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026